New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis 20 January
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference 12 January
